Stock Analiz

Calidi Biotherapeutics, Inc. CLDI

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$0.62Market cap $2M
Open the interactive analysis →

Calidi Biotherapeutics, Inc. (CLDI) is a healthcare company listed in the US with a market value of about $2M.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).

Key numbers: a P/E of 0.0, a 5-year average ROIC of -243%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 99% below the current price.

About Calidi Biotherapeutics

Calidi Biotherapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 4 years in our data. Its share count rose by 5980% over three years (dilution for shareholders).

Score: 0.8 / 5

Value2/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)0.0
Forward P/E—
P/FCF—
P/S—
P/B1.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−99%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-56504.4%
ROIC (5-yr avg.)-242.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 4 years

Fiscal year2025202420232022
Revenue———$45000
Net income-$20M-$22M-$29M-$25M
Free cash flow————
EPS (diluted)$-5.95$-35.70$-207985.98$359419.49
Net margin———-56504.4%
ROIC-264.7%-220.4%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Calidi Biotherapeutics’s P/E ratio?

About 0.0, based on the last twelve months of diluted earnings per share.

Is Calidi Biotherapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 99% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Calidi Biotherapeutics pay a dividend?

Not currently.

Is Calidi Biotherapeutics a good stock to buy?

We do not give buy or sell advice. Calidi Biotherapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.